SCHEMBL4123527

SCHEMBL4123527

CCOC(=O)CC1(O)CCN(Cc2ccccc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 4/20 0.58
CYP2D6 P10635 2/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
ALDH1A1 P00352 2/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
LMNA P02545 2/20 0.54
L3MBTL1 Q9Y468 3/20 0.53
GAA P10253 1/20 0.53
HTT P42858 1/20 0.53
POLB P06746 1/20 0.52
OPRL1 P41146 1/20 0.50
OPRM1 P35372 1/20 0.49
OPRD1 P41143 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13398822 0.95 SIGMAR1 (0.54) SIGMAR1CYP2D6CYP3A4CYP2C9CYP2C19
SCHEMBL2206046 0.88 SIGMAR1 (0.59) SIGMAR1CYP2D6CYP3A4CYP2C9CYP2C19
SCHEMBL2694056 0.86 CYP2D6 (0.54) CYP2D6CYP3A4CYP2C9CYP2C19ALDH1A1
SCHEMBL7012242 0.85 LMNA (0.67) CYP2D6CYP3A4CYP2C9CYP2C19MEN1
SCHEMBL485328 0.84 SIGMAR1 (0.55) SIGMAR1CYP2D6CYP3A4CYP2C9CYP2C19
SCHEMBL23037215 0.83 NPFFR1 (0.51) SIGMAR1CYP2D6CYP3A4CYP2C9CYP2C19
SCHEMBL7822998 0.82 CYP2D6 (0.55) SIGMAR1CYP2D6CYP3A4CYP2C9CYP2C19
SCHEMBL9228863 0.82 SIGMAR1 (0.53) SIGMAR1CYP2D6CYP3A4CYP2C9CYP2C19
SCHEMBL4023771 0.82 OPRL1 (0.59) SIGMAR1CYP2D6CYP3A4CYP2C9CYP2C19
SCHEMBL6530831 0.81 CYP2D6 (0.66) SIGMAR1CYP2D6CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease UNIVERSITE DE MONTREAL (CA) 2025-11-25 US disclosed
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE UNIVERSITE DE MONTREAL (CA) 2025-08-28 US disclosed
US-12139488-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease Université de Montréal (CA) 2024-11-12 US disclosed
US-20240317747-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-09-26 US disclosed
US-12060353-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease Université de Montréal (CA) 2024-08-13 US disclosed
US-20240217971-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-07-04 US disclosed
US-20240140945-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-05-02 US disclosed
EP-4326719-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-02-28 EP disclosed
CN-117177973-A Pyrido [3,2-D ] pyrimidine compounds and their use for the treatment of proliferative disorders 蒙特利尔大学 2023-12-05 CN disclosed
WO-2022221939-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE UNIVERSITE DE MONTREAL (CA) 2022-10-27 WO disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS SIGMAR1 4214/4885CYP2D6 824/4885CYP3A4 2998/4885
US-20240140945-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS SIGMAR1 4214/4885CYP2D6 824/4885CYP3A4 2998/4885
US-20240317747-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS SIGMAR1 4214/4885CYP2D6 824/4885CYP3A4 2998/4885
US-12139488-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, KRAS SIGMAR1 4214/4885CYP2D6 824/4885CYP3A4 2998/4885
US-12060353-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, KRAS SIGMAR1 4214/4885CYP2D6 824/4885CYP3A4 2998/4885
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, DPYD SIGMAR1 4222/4885CYP2D6 764/4885CYP3A4 2914/4885
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR SIGMAR1 2119/4885CYP2D6 1501/4885CYP3A4 1692/4885
US-20240217971-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, DPYD SIGMAR1 4222/4885CYP2D6 764/4885CYP3A4 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.